Publications

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Download PDF
Resource: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

.

Related Articles

Inhibition of histone methyltransferase EZH2 for immune interception of colorectal cancer in Lynch syndrome

Link
Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer

Link